Products for Research Use Only
RegisterLogin

GSK-LSD1

CAT: 0804-HY-100546Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100546Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
GSK-LSD1, a chemical probe, is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis[1][2][3].
CAS Number
1431368-48-7
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Histone Demethylase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Infection; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/gsk-lsd1.html
Solubility
10 mM in DMSO
Smiles
C1(N[C@H]2[C@H](C3=CC=CC=C3)C2)CCNCC1
Molecular Formula
C14H20N2
Molecular Weight
216.32
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
References & Citations
[1]Ramms B, et al. Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. Diabetes. 2022 Dec 1;71 (12) :2513-2529.|[2]Alsaqer SF, et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Jul 27;8 (43) :73372-73386.|[3]Hong KS, et al. GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro. Signal Transduct Target Ther. 2020 Nov 17;5 (1) :267.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Res Sq. 2025 Apr 01.|Adv Mater. 2021 May;33 (18) :e2100949.|Bioorg Chem. 2024 Jul 1:150:107603.|bioRxiv. 2024 Aug 19:2024.08.17.607802.|Clin Exp Med. 2025 Nov 25;26 (1) :33.|Cytokine. 2022 Mar:151:155789.|Nat Commun. 2021 Dec 8;12 (1) :7142.|Nat Commun. 2025 Feb 1;16 (1) :1241.|Nat Commun. 2025 Jan 2;16 (1) :212.|Nature. 2025 Jun;642 (8067) :508-518.|Patent. US20180263995A1.|Signal Transduct Target Ther. 2022 Apr 13;7 (1) :102.

Related Products

CatalogName
HY-173123LSD1-IN-40
HY-172809LSD1-IN-42
HY-178826LSD1-IN-45
HY-144758LSD1-IN-17
HY-161849LSD1-IN-31
HY-161869LSD1-IN-32
HY-151191LSD1-IN-22
HY-145861LSD1-IN-14
HY-160191-01LSD1-IN-30
HY-163859LSD1-IN-33

Alternative Products

CatalogName
T82254-01GSK-LSD1
bs-60179C-01GSK-LSD1 --- LSD1 Inhibitor
B4983-5GSK-LSD1 2HCl
C4202-10GSK-LSD1 (hydrochloride)
451483-01GSK LSD1 Dihydrochloride
B1258-25GSK-LSD1 dihydrochloride

Popular Products